Curt Bradshaw
Plus aucun poste en cours
Historique de carrière de Curt Bradshaw
Anciens postes connus de Curt Bradshaw
Sociétés | Poste | Début | Fin |
---|---|---|---|
ARROWHEAD PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 18/11/2019 | 01/11/2020 |
Tallac Therapeutics, Inc.
Tallac Therapeutics, Inc. BiotechnologyHealth Technology Tallac Therapeutics, Inc. engages in the development of immunomodulating polynucleotides. The company is headquartered in Burlingame, CA. | Directeur/Membre du Conseil | 01/01/2018 | 01/01/2019 |
Directeur Technique/Scientifique/R&D | 01/01/2018 | 01/01/2019 | |
Fondateur | 01/01/2018 | 01/01/2019 | |
President | 01/01/2018 | 01/01/2019 | |
Solstice Biologics LLC
Solstice Biologics LLC Pharmaceuticals: MajorHealth Technology Solstice Biologics LLC develops nucleic acid therapeutics. It specializes in the development of small, cell-permeable RNAi pro-drugs. The company was founded by Steven Dowdy and Curt W. Bradshaw in 2012 and is headquartered in San Diego, CA. | Directeur/Membre du Conseil | 01/01/2012 | 01/01/2018 |
Directeur Technique/Scientifique/R&D | 01/01/2012 | 01/01/2018 | |
Fondateur | 01/01/2012 | 01/01/2018 | |
Secrétaire Général | 01/01/2012 | 01/01/2018 | |
Treasurer | 01/01/2012 | 01/01/2018 | |
Traversa Therapeutics, Inc.
Traversa Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Traversa Therapeutics, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi Delivery Technologies. The Company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a wide variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of this platform delivery technology, as well as advancement of its own therapeutic programs for the treatment of Leukemia and Glioblastoma. The Company was founded in La Jolla, California in mid-2006, and has secured worldwide exclusive licenses to intellectual property developed during the past five years by Steven F. Dowdy, Ph.D., and his research group at the Howard Hughes Medical Institute and the University of California San Diego relating to siRNA delivery technology and induction of RNA Interference (RNAi). | Directeur Technique/Scientifique/R&D | 21/12/2009 | 19/12/2012 |
NEUBASE THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/12/2020 | - |
LIGAND PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | - | - |
ABBOTT LABORATORIES | Corporate Officer/Principal | - | - |
Pfizer Asia | Corporate Officer/Principal | - | - |
Formation de Curt Bradshaw
Texas A&M University | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 10 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 5 |
Corporate Officer/Principal | 3 |
Director/Board Member | 2 |
Sectorielle
Health Technology | 7 |
Commercial Services | 2 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 3 |
---|---|
ABBOTT LABORATORIES | Health Technology |
LIGAND PHARMACEUTICALS INCORPORATED | Health Technology |
ARROWHEAD PHARMACEUTICALS, INC. | Health Technology |
Entreprise privées | 5 |
---|---|
Traversa Therapeutics, Inc.
Traversa Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Traversa Therapeutics, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi Delivery Technologies. The Company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a wide variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of this platform delivery technology, as well as advancement of its own therapeutic programs for the treatment of Leukemia and Glioblastoma. The Company was founded in La Jolla, California in mid-2006, and has secured worldwide exclusive licenses to intellectual property developed during the past five years by Steven F. Dowdy, Ph.D., and his research group at the Howard Hughes Medical Institute and the University of California San Diego relating to siRNA delivery technology and induction of RNA Interference (RNAi). | Commercial Services |
Pfizer Asia | |
Solstice Biologics LLC
Solstice Biologics LLC Pharmaceuticals: MajorHealth Technology Solstice Biologics LLC develops nucleic acid therapeutics. It specializes in the development of small, cell-permeable RNAi pro-drugs. The company was founded by Steven Dowdy and Curt W. Bradshaw in 2012 and is headquartered in San Diego, CA. | Health Technology |
Tallac Therapeutics, Inc.
Tallac Therapeutics, Inc. BiotechnologyHealth Technology Tallac Therapeutics, Inc. engages in the development of immunomodulating polynucleotides. The company is headquartered in Burlingame, CA. | Health Technology |
NeuBase Therapeutics, Inc.
NeuBase Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The firm’s therapies are built on a proprietary platform called PATrOL that encompasses a novel peptide-nucleic acid antisense oligonucleotide technology combined with novel delivery shuttles that overcome many of the hurdles to selective mutation engagement, repeat dosing, and systemic delivery of genetic medicines. The company was founded by Dietrich A. Stephan on August 4, 2009 and is headquartered in Pittsburgh, PA. | Health Technology |
- Bourse
- Insiders
- Curt Bradshaw
- Expérience